CNS5:Diffuse hemispheric glioma, H3 G34-mutant: Difference between revisions
| [unchecked revision] | [checked revision] |
| Line 1: | Line 1: | ||
== | ==Primary Author(s)*== | ||
Xiaolin Hu, PhD, Sema4 OpCo Inc. | Xiaolin Hu, PhD, Sema4 OpCo Inc. | ||
| Line 175: | Line 175: | ||
==Gene Mutations (SNV/INDEL/Methylation)== | ==Gene Mutations (SNV/INDEL/Methylation)== | ||
<br /> | |||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
| Line 185: | Line 185: | ||
!Notes | !Notes | ||
|- | |- | ||
| | |''H3-3A'' p.G35R/V | ||
|chromosome modification | |chromosome modification | ||
|p.G35R 94% | |p.G35R 94% | ||
| Line 206: | Line 206: | ||
| | | | ||
|- | |- | ||
|MGMT | |''MGMT'' | ||
|promoter methylation | |promoter methylation | ||
|70%-74% of G34-DHG <ref name=":1" /><ref name=":4" /> | |70%-74% of G34-DHG <ref name=":1" /><ref name=":4" /> | ||
| Line 251: | Line 251: | ||
*DNA methylation and gene expression profiling can be used to differentiate G34-DHG with other glioma subgroups. | *DNA methylation and gene expression profiling can be used to differentiate G34-DHG with other glioma subgroups. | ||
*''MGMT'' promoter methylation can be assessed by methylation specific polymerase chain reaction analysis (bisulfite treated DNA undergoes real-time PCR)<br /> | *''MGMT'' promoter methylation can be assessed by methylation specific polymerase chain reaction analysis (bisulfite treated DNA undergoes real-time PCR)<br /> | ||
==References== | ==References== | ||